FineHeart Secures €83M to Revolutionize Advanced Heart Failure Treatment
January 11, 2026, 10:48 am
Location: France, Occitania, Toulouse
Employees: 11-50
Founded date: 1989
FineHeart secured €83 million in pivotal funding. This combines a €35 million Series C closing with €48 million in significant EU grants. The capital fuels FlowMaker, an innovative fully implantable cardiac output accelerator. It targets advanced heart failure patients globally. The device offers minimally invasive, physiological support, synchronized with natural heart rhythms. This breakthrough strengthens European MedTech innovation. It promises improved patient outcomes, reduced infection risks, and enhanced quality of life. FineHeart spearheads medical device sovereignty. It delivers cutting-edge cardiovascular solutions to those most in need, transforming cardiac care.
Bordeaux, France — FineHeart, a clinical-stage medical technology leader, has secured a landmark €83 million in funding. This substantial capital injection dramatically advances the fight against advanced heart failure. The financing combines a €35 million first closing of its Series C round with €48 million in strategic grants. These funds will accelerate the clinical and industrial development of FlowMaker. This innovative device promises to redefine cardiac care.
The €35 million Series C closing drew significant investor interest. New investors joined the round. Groupe Pasteur Mutualité provided crucial backing. Groupe Etchart also invested. The European Innovation Council (EIC)’s EIB fund contributed substantially. Existing investors demonstrated continued confidence. FH Founders, Lurra, IRDI, Groupe Doliam, and NACO recommitted. This broad support underscores confidence in FineHeart’s vision and technology.
The additional €48 million comes from strategic grants. The Important Project of Common European Interest (IPCEI) Tech4Cure program provided the funding. FineHeart serves as the lead partner in this critical initiative. Its role is to structure the European Active Implantable Medical Devices (AIMD) sector. This grant bolsters Europe's industrial competitiveness. It also strengthens healthcare sovereignty in medical technology. The funding supports innovations in medical devices. This includes the integration of novel digital and AI features. Six EU Member States jointly support this crucial project. France, Hungary, Italy, Latvia, Slovakia, and Slovenia are among the participating nations.
FlowMaker stands as FineHeart’s flagship innovation. It is the world's first fully implantable cardiac output accelerator. The device directly addresses advanced heart failure. This debilitating condition affects millions worldwide. FlowMaker offers a new lifeline. It targets patients with severe heart failure. Many currently find no suitable treatment options.
The device is fully intraventricular. It provides physiological support. This support synchronizes precisely with the heart’s natural contractions. It respects natural blood flow. No aortic bypass is required. This unique design minimizes stress on the heart. It ensures a more natural response.
FlowMaker’s design boasts significant advantages. It consumes minimal energy. It operates without percutaneous connections to external batteries. This eliminates a common source of infection. A transcutaneous energy transfer (TET) system recharges the device. This wireless charging improves patient quality of life dramatically. Patients can live more freely. They face fewer risks.
Implantation of FlowMaker is a minimally invasive procedure. Cardiac surgeons commonly perform it. The operation occurs on a beating heart. The average duration is approximately 90 minutes. This efficient procedure limits physiological changes for the patient. It contributes to faster recovery times. This ease of implantation makes FlowMaker broadly accessible.
Advanced heart failure represents a significant global health challenge. FineHeart initially targets 50,000 of the most severe patients. These individuals are often ineligible for current left ventricular assist devices (LVADs). This specific patient segment represents a potential market exceeding €5 billion. FlowMaker aims to fill this critical unmet medical need. It offers hope where options were previously limited.
FineHeart was founded on a bedrock of expertise. Arnaud Mascarell co-founded the company. Dr. Stéphane Garrigue serves as CSO. He invented the FlowMaker concept. Dr. Philippe Ritter, a co-inventor of cardiac resynchronization therapy (CRT), brings invaluable experience. Philippe Plas contributes extensive knowledge in cardiac rhythm management. This formidable team drives FineHeart’s innovative edge.
The company holds a robust intellectual property portfolio. It comprises 160 patents across 27 distinct families. This extensive patent protection secures FineHeart’s technological leadership. It shields its groundbreaking innovations.
This substantial funding positions FineHeart for accelerated progress. It enables rapid expansion of clinical trials. It paves the way for market entry. The company's efforts will transform advanced heart failure treatment. FineHeart aims for more predictive, personalized medicine. It champions preventive and participatory healthcare approaches.
The investment reinforces European leadership in medical technology. It showcases commitment to healthcare innovation. FineHeart’s work underscores the importance of developing cutting-edge solutions domestically. The company fosters European industrial competitiveness. It enhances medical device sovereignty. Patients suffering from advanced heart failure now have new hope. FineHeart stands at the forefront of this medical revolution. Its impact on cardiac care will be profound.
Bordeaux, France — FineHeart, a clinical-stage medical technology leader, has secured a landmark €83 million in funding. This substantial capital injection dramatically advances the fight against advanced heart failure. The financing combines a €35 million first closing of its Series C round with €48 million in strategic grants. These funds will accelerate the clinical and industrial development of FlowMaker. This innovative device promises to redefine cardiac care.
The €35 million Series C closing drew significant investor interest. New investors joined the round. Groupe Pasteur Mutualité provided crucial backing. Groupe Etchart also invested. The European Innovation Council (EIC)’s EIB fund contributed substantially. Existing investors demonstrated continued confidence. FH Founders, Lurra, IRDI, Groupe Doliam, and NACO recommitted. This broad support underscores confidence in FineHeart’s vision and technology.
The additional €48 million comes from strategic grants. The Important Project of Common European Interest (IPCEI) Tech4Cure program provided the funding. FineHeart serves as the lead partner in this critical initiative. Its role is to structure the European Active Implantable Medical Devices (AIMD) sector. This grant bolsters Europe's industrial competitiveness. It also strengthens healthcare sovereignty in medical technology. The funding supports innovations in medical devices. This includes the integration of novel digital and AI features. Six EU Member States jointly support this crucial project. France, Hungary, Italy, Latvia, Slovakia, and Slovenia are among the participating nations.
FlowMaker stands as FineHeart’s flagship innovation. It is the world's first fully implantable cardiac output accelerator. The device directly addresses advanced heart failure. This debilitating condition affects millions worldwide. FlowMaker offers a new lifeline. It targets patients with severe heart failure. Many currently find no suitable treatment options.
The device is fully intraventricular. It provides physiological support. This support synchronizes precisely with the heart’s natural contractions. It respects natural blood flow. No aortic bypass is required. This unique design minimizes stress on the heart. It ensures a more natural response.
FlowMaker’s design boasts significant advantages. It consumes minimal energy. It operates without percutaneous connections to external batteries. This eliminates a common source of infection. A transcutaneous energy transfer (TET) system recharges the device. This wireless charging improves patient quality of life dramatically. Patients can live more freely. They face fewer risks.
Implantation of FlowMaker is a minimally invasive procedure. Cardiac surgeons commonly perform it. The operation occurs on a beating heart. The average duration is approximately 90 minutes. This efficient procedure limits physiological changes for the patient. It contributes to faster recovery times. This ease of implantation makes FlowMaker broadly accessible.
Advanced heart failure represents a significant global health challenge. FineHeart initially targets 50,000 of the most severe patients. These individuals are often ineligible for current left ventricular assist devices (LVADs). This specific patient segment represents a potential market exceeding €5 billion. FlowMaker aims to fill this critical unmet medical need. It offers hope where options were previously limited.
FineHeart was founded on a bedrock of expertise. Arnaud Mascarell co-founded the company. Dr. Stéphane Garrigue serves as CSO. He invented the FlowMaker concept. Dr. Philippe Ritter, a co-inventor of cardiac resynchronization therapy (CRT), brings invaluable experience. Philippe Plas contributes extensive knowledge in cardiac rhythm management. This formidable team drives FineHeart’s innovative edge.
The company holds a robust intellectual property portfolio. It comprises 160 patents across 27 distinct families. This extensive patent protection secures FineHeart’s technological leadership. It shields its groundbreaking innovations.
This substantial funding positions FineHeart for accelerated progress. It enables rapid expansion of clinical trials. It paves the way for market entry. The company's efforts will transform advanced heart failure treatment. FineHeart aims for more predictive, personalized medicine. It champions preventive and participatory healthcare approaches.
The investment reinforces European leadership in medical technology. It showcases commitment to healthcare innovation. FineHeart’s work underscores the importance of developing cutting-edge solutions domestically. The company fosters European industrial competitiveness. It enhances medical device sovereignty. Patients suffering from advanced heart failure now have new hope. FineHeart stands at the forefront of this medical revolution. Its impact on cardiac care will be profound.